https://www.selleckchem.com/products/cx-5461.html
© 2020 The Authors. Molecular Genetics Genomic Medicine published by Wiley Periodicals LLC.For patients who have chronic myeloid leukemia (CML), one of the primary treatment options is administration of nilotinib 300 mg twice daily (BID). In previous studies which compared outcomes associated with nilotinib or imatinib treatment, nilotinib achieved a higher rate of deep molecular response (MR). We conducted a phase II, open-label, multicenter study to investigate an intrapatient nilotinib dose-escalation strategy for patients with
Gefällt mir
Kommentar
Teilen
